Medication for management of pregnancy-induced hypertension

Hypertension refers to increased arterial blood pressure and can be divided into two categories: primary and secondary. Primary hypertension caused by angiogenic degenerative changes is a degenerative disease. With liberalization of China’s reproduction policy and increases in maternal age, the prevalence of pregnancy-induced hypertension (PIH) in China has increased gradually. PIH is not a type of primary hypertension, but there are differences in the treatment of these two types of hypertension. Here, we review the choice and use of drugs for PIH management using drugs for the management of primary hypertension as a reference. First-line drugs such as labetalol, nifedipine, or methyldopa should be taken via the oral route if blood pressure is ≥ 150/90 mmHg. For chronic hypertension, other drugs should be added after the first drug at the highest concentration has been revealed to be ineffective. If the blood pressure of patients with acute hypertension is ≥ 160/110 mmHg, maternal stroke or eclampsia can result. If PIH patients are about to deliver, they can be given labetalol (i.v.), hydralazine (i.v.) or nifedipine (p.o.). Moreover, all anti-hypertensive treatments should be based on considerations of maternal and fetal safety.

Pregnancy Induced Hypertension – Nursing Care and Management

Cover Story Gestational Hypertension and Preeclampsia: Nontraditional Risk Factors For Cardiovascular Disease - American College of Cardiology

Treatment for Mild Chronic Hypertension during Pregnancy

Gestational hypertension

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial - The Lancet

A case of bilateral pheochromocytoma during pregnancy – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.

Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses

Hypertensive Disorders of Pregnancy

New targets, guidance reframe treatment of hypertensive disorders of pregnancy